Abstract
Diabetic neuropathy is the most common cause of neuropathy worldwide and it is estimated to affect about half of people with diabetes. The goal of our study is to compare the effectiveness of thioctic acid treatment alone versus the efficacy of thioctic acid plus vitamin B complex in patients with diabetic peripheral polyneuropathy (DPN). We conducted a prospective, observational study staring from October 2017 to December 2018, in which we included 56 DPN patients. Depending on the Michigan neuropathic screening instrument (MNSI) we divided the patients into two subgroups: patients with MNSI <7 and patients whose MNSI did not decrease sufficiently during the therapeutic protocol. 36 patients (64.2%) of the total patients enrolled in the study had an MNSI <7 at one of the follow-up meetings. These patients were also divided according to the therapeutic protocol applied in a group of patients who were treated with only thioctic acid (TA group) and in a group of patients who were treated with thioctic acid plus vitamin B complex (TA + B group). We noticed a greater proportion of patients who had a MNSI <7 in the TA + B group. This study revealed that the treatment of peripheral diabetic neuropathy with thioctic acid plus Vitamin B complex compared to thioctic acid alone was superior in terms of improving clinical features. Keywords: diabetes mellitus, thioctic acid, Vitamin B complex, diabetic peripheral neuropathy
Highlights
Diabetic neuropathy is the most common cause of neuropathy worldwide and it is estimated to affect about half of people with diabetes
The inclusion criteria in the study were the presence of diabetes, diagnosed according to the American Diabetes Association criteria [8-10], the diagnosis of peripheral diabetic neuropathy sustained by both the clinical examination performed by a senior neurologist and the assessment of nerve conduction, the patients’ acceptance to participate in the study and to be present in the followup, and the glycemic profile controlled by the diabetologist for at least 3 months prior to inclusion in our study
In our study, we prospectively included 56 patients diagnosed with peripheral diabetic neuropathy (DPN). 23 patients were enrolled in the TA group and 23 patients were enrolled in the TA + B group
Summary
Diabetic neuropathy is the most common cause of neuropathy worldwide and it is estimated to affect about half of people with diabetes. The goal of our study is to compare the effectiveness of thioctic acid treatment alone versus the efficacy of thioctic acid plus vitamin B complex in patients with diabetic peripheral polyneuropathy (DPN). 36 patients (64.2%) of the total patients enrolled in the study had an MNSI
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
